To address these differing cancer risks, a new classification system for LS has been proposed based on genetic diagnosis, in which the underlying gene affected is designated (e.g., MSH2-LS), and clinical surveillance recommendations are tailored accordingly [5]. This evidence concerns the gene MSH2 and Leigh syndrome.